Free tool
FAERS Monitor: Emtriva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021896 or its brand name (Emtriva, Emtricitabine). Reports on generic versions are filed under their own applications.
Reports
7,211
Serious
6,881
95% of reports
Hospitalization
2,167
Death reported
901
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction663
- foetal exposure during pregnancy622
- drug resistance437
- anxiety432
- virologic failure407
- drug ineffective331
- immune reconstitution inflammatory syndrome300
- off label use279
- pain264
- emotional distress239
- depression235
- exposure during pregnancy229
- pathogen resistance220
- acute kidney injury213
- renal failure205
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 81 |
| 2005 | 95 |
| 2006 | 115 |
| 2007 | 123 |
| 2008 | 154 |
| 2009 | 198 |
| 2010 | 129 |
| 2011 | 141 |
| 2012 | 118 |
| 2013 | 240 |
| 2014 | 245 |
| 2015 | 390 |
| 2016 | 568 |
| 2017 | 582 |
| 2018 | 646 |
| 2019 | 686 |
| 2020 | 709 |
| 2021 | 496 |
| 2022 | 510 |
| 2023 | 396 |
| 2024 | 261 |
| 2025 | 207 |
| 2026 | 121 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,948 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| virologic failureSignal | 407 | 238.7 | 216.4 | 88,869 |
| immune reconstitution inflammatory syndromeSignal | 300 | 186.8 | 166.6 | 51,939 |
| pathogen resistanceSignal | 220 | 72.1 | 63.2 | 14,994 |
| drug resistanceSignal | 437 | 50.5 | 46.0 | 20,803 |
| foetal exposure during pregnancySignal | 622 | 22.5 | 20.8 | 12,699 |
| drug interactionSignal | 663 | 12.2 | 11.4 | 6,853 |
| exposure during pregnancySignal | 229 | 10.8 | 9.5 | 2,021 |
| emotional distressSignal | 239 | 5.8 | 5.1 | 941 |
| renal failureSignal | 205 | 4.5 | 3.9 | 559 |
| anxietySignal | 432 | 4.4 | 4.0 | 1,159 |
| acute kidney injurySignal | 213 | 4.1 | 3.6 | 492 |
| depressionSignal | 235 | 3.0 | 2.7 | 317 |
| pain | 264 | 1.3 | 1.1 | 14 |
| off label use | 279 | 0.9 | 0.8 | 1 |
| drug ineffective | 331 | 0.7 | 0.7 | 34 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.